Bill Kim, MD
Gastroenterology · Soldotna, AKNPI 1255438727
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,850 of the $55,599 with a category attached, or 87.9%. AbbVie accounts for 94.7% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $32,030 and has fallen 99.6% since, to $138 in 2025. Among gastroenterology clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $356.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$53K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Lilly USA, LLC$294
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$227
- Bristol Myers Squibb$193
- Gilead$136
- plus $995 from 17 others
What the payments were for
- Consulting fees$8101%
- Speaking & faculty fees$48,85088%
- Travel & lodging$2,3634%
- Food & beverage$3,5236%
- Gifts$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $52,643 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $1,111 |
| Lilly USA, LLC | 4 | $294 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $227 |
| Bristol Myers Squibb | 16 | $193 |
| Gilead | 8 | $136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $135 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Braintree Laboratories, Inc. | 5 | $121 |
| Ardelyx, Inc. | 4 | $97 |
| Regeneron Healthcare Solutions, Inc. | 1 | $90 |
| Nestle Healthcare Nutrition Inc. | 5 | $84 |
| Intercept Pharmaceuticals, Inc. | 4 | $82 |
| Hydrofera LLC | 1 | $47 |
| Pfizer | 2 | $38 |
| Shire North American Group Inc | 2 | $31 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Regeneron | 1 | $25 |
| Fresenius Kabi USA, LLC | 1 | $23 |
| Olympus America Inc. | 1 | $17 |
| GSK | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,599 in reported general payments places this provider in the 95th percentile of 23 gastroenterology providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 45 | $134,861 |
| CreonLipase/Protease/Amylase | 22 | $33,252 |
| LinzessLinaclotide | 44 | $30,793 |
| VoqueznaVonoprazan Fumarate | 22 | $16,114 |
| MovantikNaloxegol Oxalate | 24 | $9,384 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 124 | $8,643 |
| TrulancePlecanatide | 13 | $8,237 |
| Vancomycin Hcl | 19 | $7,857 |
| Colesevelam Hcl | 34 | $5,311 |
| Mesalamine | 18 | $4,339 |
| Ursodiol | 17 | $2,244 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 12 | $1,927 |
| Budesonide DrBudesonide | 17 | $1,418 |
| Lubiprostone | 13 | $810 |
| Ondansetron OdtOndansetron | 11 | $742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $52,643 | $64,04466 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $135 | $8,23713 claims |
| Braintree Laboratories, Inc.Sutab | $121 | $1,92712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 23 gastroenterology providers in Alaska.
Other gastroenterology in Soldotna
- Daryl McClendonAnchorage$6K
- Brian SweeneyAnchorage$6K
- Austin NelsonAnchorage$5K
- Jeffery MolloyAnchorage$5K
- Jared BeckPalmer$2K
- Farhoud KhosraviPalmer$2K
- Michelle RandolphAnchorage$1K
- Blair CurtisJber$718
- Kavya Kelagere MayigegowdaAnchorage$710
- Martin KaszubowskiAnchorage$646
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.